NCT07494461

Brief Summary

People with Parkinson's disease (PD) may have difficulty stopping or changing their movements, especially when walking around obstacles. The goal of this observational study is to learn if a specific cognitive function, called inhibitory control (the ability to stop or control actions) is associated with gait adaptability in people with Parkinson's disease. Gait adaptability means the ability to adjust how a person walks in response to changes in the environment, such as stepping over obstacles. The main questions the study aims to answer are:

  • If brain activation related to inhibitory control, measured by EEG, is associated with gait adaptability during obstacle crossing in people with Parkinson's disease?
  • If behavioral inhibitory control is associated with gait adaptability during obstacle crossing in people with Parkinson's disease? Participants take part in one study visit. During this visit, participants complete simple thinking tests, have their brain activity recorded using EEG, and perform walking tasks that include stepping over obstacles.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
40mo left

Started Apr 2026

Typical duration for all trials

Geographic Reach
1 country

2 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress4%
Apr 2026Aug 2029

First Submitted

Initial submission to the registry

March 20, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 27, 2026

Completed
5 days until next milestone

Study Start

First participant enrolled

April 1, 2026

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2029

Last Updated

March 27, 2026

Status Verified

March 1, 2026

Enrollment Period

3.4 years

First QC Date

March 20, 2026

Last Update Submit

March 20, 2026

Conditions

Parkinson Disease (PD)

Keywords

ElectroencephalographyExecutive functionObstacle crossing

Outcome Measures

Primary Outcomes (11)

  • Event-related potential - N2

    Measure event-related potential through electroencephalography during the Go/No-go test

    1 day

  • Event-related potential - P300

    Measure event-related potential through electroencephalography during the Go/No-go test

    1 day

  • Stroop color and word test

    Record numbers of corrected color words which the subject responds within 45 sec

    1 day

  • Step width

    Using the GAITRite system to measure step width

    1 day

  • Stride length/Step length

    Using the GAITRite system to measure stride length and step length during obstacle crossing

    1 day

  • Single support time

    Using the GAITRite system to measure single support time during obstacle crossing

    1 day

  • Gait speed

    Gait speed during obstacle crossing was measured using the GAITRite system. Continuous obstacle-crossing walking performance was assessed using the GaitUp system.

    1 day

  • Stride length

    Using the GaitUp system to measure stride length during continuous obstacle-crossing walking.

    1 day

  • Swing phase

    Using the GaitUp system to measure swing phase during continuous obstacle-crossing walking.

    1 day

  • Swing width

    Using the GaitUp system to measure swing width during continuous obstacle-crossing walking.

    1 day

  • Four Square Step Test

    The Four Square Step Test is a test used to assess the ability to step over objects and measures the time in seconds to navigate all four squares.

    1 day

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Community

You may qualify if:

  • A clinical diagnosis of idiopathic Parkinson's disease;
  • Stable use of prescribed antiparkinsonian medication for at least two weeks;
  • Modified Hoehn and Yahr stage I to III;
  • Age between 18 and 80 years;
  • Ability to ambulate independently for at least 30 meters without assistive devices;
  • A Mini-Mental State Examination (MMSE) score of ≥ 24;
  • Corrected vision and hearing sufficient to effectively receive external stimuli

You may not qualify if:

  • The presence of any neurological, musculoskeletal, or cardiovascular disorders that could affect participation in this study;
  • The presence of psychiatric disorders that could interfere with the ability to follow instructions or comply with study procedures;
  • A history of brain surgery, such as deep brain stimulation (DBS)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

National Yang Ming Chiao Tung University

Taipei, Taiwan

Location

National Yang Ming Chiao Tung University

Taipei, Taiwan

Location

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Central Study Contacts

Yea-Ru Yang, PhD

CONTACT

+886228267279yryang@nycu.edu.tw

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 20, 2026

First Posted

March 27, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

August 31, 2029

Study Completion (Estimated)

August 31, 2029

Last Updated

March 27, 2026

Record last verified: 2026-03

Locations

TW(2)